πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10851112

Anti-HCMV virus compound

Medshine Discovery Inc. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851173

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10844137

Anti-CTLA-4 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829550

Polynucleotides encoding anti-CXCL13 antibodies

VACCINEX, INC. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822427

Anti-CSPG4 fusions with interferon for the treatment of malignancy

The Regents of the University of California Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822588

Agents and methods to elicit anti-tumor immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822426

Humanized anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822414

Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using an

Sutro Biopharma, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815301

Anti-CD30 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806780

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10793636

Anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. Β· Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10786552

Il-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10787501

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10781255

Anti-CD83 antibodies and use thereof

The Regents of the University of California Β· Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10772972

Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758613

Combination therapies using anti-metabolites and agents that target tumor-associated strom

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFERβ€”NATIONAL INSTITUTES OF HEALTH Β· Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752701

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752702

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752699

Anti-APOBEC3 antibodies and methods of making and using

Regents of the University of Minnesota Β· Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752656

Anti-microbial supramolecular structures

Northwestern University Β· Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10744116

Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

The Regents of the University of California Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10745481

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738126

Anti-GITR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736976

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted